[The CLASS study and its scientific statement. Ethical publishing rules neglected].
Wollheim
Frank A
FA
Reumatologiska kliniken, Universitetssjukhuset i Lund. Frank.Wollheim@reum.lu.se
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068579:Celecoxib; D016265:Conflict of Interest; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000627:therapeutic use; D010506:Periodicals as Topic; D017594:Publication Bias; D011643:Publishing / Q000941:ethics* / Q000592:standards; D011720:Pyrazoles; D016032:Randomized Controlled Trials as Topic / Q000941:ethics / Q000592:standards; D012109:Research Support as Topic / Q000941:ethics; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use; D013450:Sulfones
D018501:Antirheumatic Agents; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib